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Objectives: Data on cephalosporin consumption in the community were collected from 30 EU/EEA countries
over two decades. This article reviews temporal trends, seasonal variation, presence of change-points and
changes in the composition of the main subgroups of cephalosporins.
Methods: For the period 1997–2017, data on consumption of cephalosporins (i.e. first-, second-, third- and
fourth-generation cephalosporins; ATC subgroups J01DB, J01DC, J01DD and J01DE, respectively) in the commu-
nity and aggregated at the level of the active substance, were collected using the WHO ATC/DDD methodology
(ATC/DDD index 2019). Consumption was expressed in DDD per 1000 inhabitants per day and in packages per
1000 inhabitants per day. Cephalosporin consumption was analysed based on ATC-4 subgroup, and presented
as trends, seasonal variation, presence of change-points and compositional changes.
Results: In 2017, cephalosporin consumption in the community expressed in DDD per 1000 inhabitants per day
varied by a factor of 285 between countries with the highest (Greece) and the lowest (the Netherlands) con-
sumption. Cephalosporin consumption did not change significantly between the first quarter of 1997 and the
last quarter of 2017. Seasonal variation decreased significantly over time. Proportional consumption of second-
and third-generation cephalosporins significantly increased over time compared with that of first-generation
cephalosporins, and proportional consumption of fourth-generation cephalosporins significantly decreased
compared with that of second- and third-generation cephalosporins.
Conclusions: Despite considerable variation between countries in the composition of cephalosporin consump-
tion and trends over time, a significant shift towards consumption of more broad-spectrum cephalosporins in
the community was observed across the EU/EEA during 1997–2017.
Introduction
This article presents data from the European Surveillance of
Antimicrobial Consumption Network (ESAC-Net,1 formerly ESAC)
on consumption of cephalosporins in the community (i.e. primary
care sector) for 30 EU/EEA countries in 2017. Because consumption
of monobactams, carbapenems and other cephalosporins and
penems is very small in the community in EU/EEA countries, this
article focusses on consumption of first-, second-, third- and
fourth-generation cephalosporins (Table 1).2 The present study
updates previous ESAC studies published in 2006 and 2011, and in
doing so it provides updated comparable and reliable information
on antibiotic consumption that can aid in fighting the global prob-
lem of antimicrobial resistance.3,4 In 2017, cephalosporins repre-
sented 11.6% of antibiotic consumption in the community.5 The
objective of this study was to analyse temporal trends, seasonal
variation and the presence of change-points in cephalosporin
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consumption in the community for the period 1997–2017, as well
as to analyse the composition of cephalosporin consumption over
time.
Methods
The methods for collecting and analysing the data are described in the
introductory article of this series.6 In summary, data on consumption of
cephalosporins, i.e. first-, second-, third- and fourth-generation cephalo-
sporins (ATC groups J01DB, J01DC, J01DD and J01DE, respectively), aggre-
gated at the level of the active substance, were collected using the WHO
ATC/DDD methodology (ATC/DDD index 2019) and expressed in DDD per
1000 inhabitants per day. In addition, where data were available, cephalo-
sporin consumption was expressed in packages per 1000 inhabitants per
day. There are 51 unique ATC codes for cephalosporins in the ATC/DDD
index 2019. Compared with previous descriptions of the consumption of
cephalosporins in the community,4 three additional second-generation
cephalosporins and three additional third-generation cephalosporins have
been assigned an ATC code by the WHO (Table 1).
The evolution of the number of DDD per package over time was
assessed using a linear mixed model. The temporal trend, seasonal vari-
ation and presence of change-points in cephalosporin consumption were
assessed using a non-linear change-point mixed model fitted to quarterly
data expressed in DDD per 1000 inhabitants per day from 1997 to 2017.7
The relative proportions of the main subgroups were assessed through a
compositional data analysis modelling yearly data expressed in DDD per
1000 inhabitants per day from 1997 to 2017.8
Results
An overview of consumption of cephalosporins (ATC J01DB, J01DC,
J01DD and J01DE) in the community, expressed in DDD and pack-
ages per 1000 inhabitants per day for all participating countries
between 1997 and 2017 is available as Supplementary data at
JAC Online (Tables S1 and S2, respectively).
Cephalosporin consumption in the community in 2017
In 2017, five substances accounted for 90% of cephalosporin
consumption in the community expressed in DDD per 1000 inhabi-
tants per day: cefuroxime (63.0% in 2017 compared with 56.5%
in 2009), cefixime (8.9% in 2017 compared with 7.3% in 2009),
cefalexin (8% in 2017 compared with 9.5% in 2009), cefaclor
(7.2% in 2017 compared with 10.1% in 2009) and cefpodoxime
(3.1% in 2017 compared with 3.1% in 2009) (Table 1).
Figure 1 shows the consumption of cephalosporins in the com-
munity subdivided into the four generations expressed in DDD per
Table 1. Classification of cephalosporins (J01DB, J01DC, J01DD and J01DE; ATC/DDD index 2019)
First-generation Second-generation Third-generation Fourth-generation
J01DB01 Cefalexina J01DC01 Cefoxitin J01DD01 Cefotaxime J01DE01 Cefepime
J01DB02 Cefaloridineb J01DC02 Cefuroximea J01DD02 Ceftazidime J01DE02 Cefpirome
J01DB03 Cefalotin J01DC03 Cefamandole J01DD03 Cefsulodinb J01DE03 Cefozopranb
J01DB04 Cefazolin J01DC04 Cefaclora J01DD04 Ceftriaxone
J01DB05 Cefadroxil J01DC05 Cefotetanb J01DD05 Cefmenoximeb
J01DB06 Cefazedoneb J01DC06 Cefonicide J01DD06 Latamoxefb
J01DB07 Cefatrizine J01DC07 Cefotiam J01DD07 Ceftizoxime
J01DB08 Cefapirinb J01DC08 Loracarbef J01DD08 Cefiximea
J01DB09 Cefradine J01DC09 Cefmetazoleb J01DD09 Cefodizime
J01DB10 Cefacetrileb J01DC10 Cefprozila J01DD10 Cefetametb
J01DB11 Cefroxadineb J01DC11 Ceforanide J01DD11 Cefpiramideb
J01DB12 Ceftezoleb J01DC12 Cefminoxc J01DD12 Cefoperazone
J01DC13 Cefbuperazonec J01DD13 Cefpodoximea




J01DD51 Cefotaxime and BLIc
J01DD52 Ceftazidime and BLIc
J01DD54 Ceftriaxone
combinations
J01DD62 Cefoperazone and BLI
J01DD63 Ceftriaxone and BLIc
BLI, b-lactamase inhibitor; Bold type indicates that consumption was part of the top 90% of the community consumption of cephalosporins (J01DB,
J01DC, J01DD and J01DE) in 28 EU/EEA countries in 2017; Italic type indicates that no consumption of this cephalosporin was reported in 28 EU/EEA
countries in 2017.
aConsumption was part of the top 90% of the community consumption of cephalosporins (J01DB, J01DC, J01DD and J01DE) in 30 EU/EEA countries in
2009.
bNo consumption of this cephalosporin was reported in 30 EU/EEA countries in 2009.
cThis cephalosporin was not included in the ATC/DDD index in 2009 and was therefore not reported in 2009.
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1000 inhabitants per day for 30 EU/EEA countries in 2017.
Cephalosporin consumption in the community varied by a factor of
285 between the countries with the highest (7.65 DDD per 1000
inhabitants per day in Greece) and the lowest (0.03 DDD per 1000
inhabitants per day in the Netherlands) consumption, which was
similar compared with 2009 (factor of 267, from 8.7 DDD per 1000
inhabitants per day in Greece to 0.03 DDD per 1000 inhabitants per
day in Denmark). Inter-country variations were high when com-
paring consumption of first-, second-, third- and fourth-generation
cephalosporins (Table S1).
In 2017, first-generation cephalosporins represented 10.6%
(14% in 2009) of cephalosporin consumption in the community.
Consumption was the highest in Northern EU/EEA countries such
as Finland (98.9% of cephalosporin consumption in the commu-
nity), Iceland (98.2%), Sweden (97.3%), Norway (90.3%) and the
United Kingdom (89.8%) and the lowest (<1%) in Greece, Hungary
and Luxembourg. First-generation cephalosporin consumption
was mostly represented by one substance, namely cefalexin
(J01DB01), in Croatia, Finland and Malta (100%) and Iceland
(99.4%). Cefadroxil (J01DB05) was the preferred first-generation
cephalosporin in Estonia and Latvia (>90%) and in Lithuania
(>80%). Cefradine (J01DB09) was only consumed in the United
Kingdom (5.6%), Portugal (3.8%) and France (2.2%). First-gener-
ation cephalosporins represented <5% of cephalosporin consump-
tion in the community in Belgium, Bulgaria, France, Germany,
Greece, Hungary, Italy, Luxembourg, Malta, Spain, Romania (total
care data, i.e. community and hospital sector combined) and
Cyprus (total care data).
In 2017, second-generation cephalosporins represented 73.0%
(71.5% in 2009) of cephalosporin consumption in the community.
The second-generation cephalosporins represented >60% of
cephalosporin consumption in the community in 21 EU/EEA coun-
tries. Consumption was the highest for cefuroxime (J01DC02),
which represented >50% of second-generation cephalosporin
consumption in the community in all but three countries (Ireland,
Sweden, United Kingdom). Ireland had the highest consumption
of cefaclor (J01DC04; 60.4%). Countries with the highest consump-
tion of cefprozil (J01DC10) were Hungary (16.2%), Greece (10.3%)
and Estonia (6.6%). Greece was the only country using ceforanide
(J01DC11).
In 2017, third-generation cephalosporins represented 16.4%
(14.5% in 2009) of cephalosporin consumption in the community.
These were mostly cefixime (J01DD08), cefpodoxime (J01DD13)
and ceftriaxone (J01DD04), from which 20.6% was for parenteral
use (mainly ceftriaxone). The highest consumption of third-gener-
ation cephalosporins was observed for Italy (>80% of cephalo-
sporin consumption, of which mainly cefixime for oral use), France
(>70%, mainly the oral substances cefpodoxime and cefixime),
Romania (total care data: 26.0%, mainly cefixime and ceftriaxone),
and Cyprus (total care data: 18.1%, mainly cefixime).
In 2017, 16 EU/EEA countries reported consumption of fourth-
generation cephalosporins in the community. This consumption
was very low, only representing 0.01% (0.02% in 2009) of cephalo-
sporin consumption in the community in the EU/EEA. The highest
consumption of fourth-generation cephalosporins was observed
for Italy (0.15%). The only fourth-generation cephalosporin con-
sumed was cefepime (J01DE01), with the exception of cefpirome
(J01DE02) in Bulgaria.
Figure 2 shows cephalosporin consumption in the community
































































































































































Figure 1. Consumption of cephalosporins (ATC J01DB, J01DC, J01DD and J01DE) in the community, expressed in DDD (ATC/DDD index 2019) per
1000 inhabitants per day, 30 EU/EEA countries, 2017. For Czechia, 2015 data are used. For Slovakia, 2016 data are used. For Cyprus and Romania,
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countries in 2017. Portugal ranked 9th for its cephalosporin con-
sumption in DDD per 1000 inhabitants per day and 15th in pack-
ages per 1000 inhabitants per day, Spain 5th and 11th, Italy 8th
and 2nd, and France 10th and 3rd, respectively (Table 2). The num-
ber of DDD per package ranged from 1.8 in Italy to 11.4 in Portugal.
In the EU/EEA countries, the number of DDD per package did not
change significantly over time during the period 1997–2017.
Longitudinal data analysis, 1997–2017
The best fit was obtained for a model including two change-points:
one in the last quarter of 2003 and another in the second quarter
of 2011. The final model fits the observed data well (Figure S1).
The longitudinal data analysis estimated an average cephalo-
sporin consumption in the EU/EEA of 2.154 (SE 0.425) DDD per
1000 inhabitants per day in the first quarter of 1997, which did not
change significantly over time: #0.003 (SE 0.006) DDD per 1000
inhabitants per day per quarter up to the last quarter of 2003;
!0.006 (SE 0.013) DDD per 1000 inhabitants per day per quarter
until the second quarter of 2011; and !0.009 (SE 0.015) DDD per
1000 inhabitants per day per quarter afterwards. Furthermore, the
longitudinal data analysis showed significant seasonal variation
with an amplitude of 0.616 (SE 0.09) DDD per 1000 inhabitants per
day, which decreased significantly over time with 0.004 (SE 0.001)
DDD per 1000 inhabitants per day per quarter (Figure 3). The sea-
sonal variation in cephalosporin consumption is shown in Figures
S2 and S3. Seasonal variations were observed in all countries.
Based on the fitted model, cephalosporin consumption in the
community in 1997 was significantly higher than average in
Belgium, Cyprus (total care data), Greece, Italy, Luxembourg and
Portugal, and significantly lower than average in Denmark,
Estonia, Germany, Iceland, Lithuania, the Netherlands, Slovenia,
Sweden and the United Kingdom. The decrease in cephalosporin
consumption between 1997 and the last quarter of 2003 was sig-
nificantly larger than average in Belgium, Hungary and Spain, and
smaller than average in Croatia and Slovakia. The increase in ceph-
alosporin consumption between the first quarter of 2004 and the
second quarter of 2011 was significantly larger than average in
Germany, Lithuania and Slovakia. The increase in cephalosporin
consumption between the third quarter of 2011 and 2017 was sig-
nificantly larger than average in Lithuania and Slovakia. Seasonal
variation was significantly larger than average in Belgium,
Germany, Greece, Hungary, Italy, Luxembourg, Portugal and
Slovakia, and significantly smaller than average in Denmark,
Estonia, Finland, Iceland, Lithuania, the Netherlands, Slovenia,
Sweden and the United Kingdom.
Between 2009 and 2017 cephalosporin consumption increased
in 12 EU/EEA countries (Table S1). This increase was the highest in
Bulgaria followed by Spain, Poland and Romania. Iceland, a coun-
try with low cephalosporin consumption in the community, has
doubled its consumption since 2009, mainly due to an increase in
the consumption of the first-generation cephalosporin cefalexin.
As in 2009, the Netherlands and Denmark still had the lowest con-
sumption of cephalosporins in the community in 2017. The
Netherlands even showed a further decrease mainly due to the
continuous decrease in the consumption of the second-generation
cephalosporins (cefaclor and cefuroxime), but also the third-gen-
eration cephalosporin ceftibuten. Fourth-generation cephalospor-
ins were not consumed in most northern EU/EEA countries, or














































































































Figure 2. Consumption of cephalosporins (ATC J01DB, J01DC, J01DD and J01DE combined) in the community, expressed in packages per 1000 inhab-
itants per day, 20 EU/EEA countries, 2017. For Czechia, 2015 data are used. For Slovakia, 2016 data are used. For Cyprus and Romania, total care
data, i.e. community and hospital sector combined, are used.
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Compositional data analysis, 2009–2017
The proportional consumption of both second- and third-gener-
ation cephalosporins significantly increased over time relative to
that of first- and fourth-generation cephalosporins. The propor-
tional consumption of third-generation cephalosporins significant-
ly increased relative to that of second-generation cephalosporins
(Table 3).
Trends of proportional consumption in individual countries are
shown in Figure S4. When comparing the composition of the
consumption of cephalosporins in 2017 with that in 2009, both
increases and decreases were observed. For first-generation
cephalosporins, changes were substantial, with increases >10%
reported for Iceland (!58.37%), Sweden (!21.94%) and Ireland
(!13.37%), and decreases >10% reported for Bulgaria (#33.72%),
Latvia (#29.89%), Lithuania (#28.57%), Croatia (#13.64%), and
Estonia (#12.33%). In addition, increases >5% were reported for
three countries (Austria, the Netherlands and Slovenia) while
decreases >5% were reported for five countries [Czechia (2015
data), Denmark, Norway, Portugal and Romania (total care data;
coverage in 2009 limited to 30%–40%)]. The increase observed for
the Netherlands was minimal in absolute value with consumption
of first-generation cephalosporins consistently representing <0.01
DDD per 1000 inhabitants per day. Substantial decreases were
observed due to the discontinuation of cefatrizine (J01DB07) in
four countries and of cefradine (J01DB09) in nine countries. The
changes in proportions of first-generation cephalosporins were
matched by changes in proportions of either second-generation or
third-generation cephalosporins. For second- and third-generation
cephalosporins, decreases >5% were observed for 10 and 7 coun-
tries, respectively, while increases >5% were observed for 11 and 8
countries, respectively. The largest changes in the proportional
consumption of second-generation cephalosporins were observed
for Lithuania (!34.20%) and Latvia (!30.01%), and for Iceland
(#59.39%). The largest changes in the proportional consumption
of third-generation cephalosporins were observed for Romania
(!22.11%; total care data; coverage in 2009 limited to 30%–40%)
and Malta (!15.91%), and for Austria (#27.91%). Changes in the
proportional consumption of fourth-generation cephalosporins
were minimal and never exceeded 1%.
Discussion
This study describes the consumption of cephalosporins in the
community in the EU/EEA. The longitudinal data analysis showed
no significant changes in the trend of cephalosporin consumption
between 1997 and 2017. On the other hand, its seasonal variation
decreased significantly over time. We also observed considerable
variation in trends and composition over time at the country level.
Overall, the significantly increasing consumption of second- and
third-generation cephalosporins went hand-in-hand with a pro-
portional decrease of first-generation cephalosporins in most
countries. These trends had already been observed for the period
1997–2009.4
The proportional consumption of cephalosporins (a subgroup
of other b-lactam antibacterials, ATC group J01D) out of all anti-
bacterials for systemic use (J01) in 2017 ranged from 0.22%
in Denmark to 23.96% in Greece.5 In 2017, consumption of cepha-
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ESAC-Net but covered by the WHO Europe Antimicrobial Medicines
Consumption (AMC) Network also showed considerable variation
and ranged between 9.5% (Armenia) to 27.5% (Uzbekistan) of
total, i.e. community and hospital sector combined, consumption
of antibacterials for systemic use (J01).9
A remarkable gradient in cephalosporin consumption was
observed in the EU/EEA, with a higher consumption and seasonal
variation in southern and eastern countries than in northern coun-
tries. However, while the countries with the highest cephalosporin
consumption in the community, i.e. Greece and Cyprus (total care
data), decreased their consumption, it nearly doubled in Bulgaria
and Romania (total care data; coverage in 2009 limited to
30%–40%). In Malta, after a considerable increase up to 2009,
consumption of, mostly second-generation, cephalosporins has
decreased since 2014. Furthermore, we observed a continuous
decreasing trend of cephalosporin consumption in the community
in several countries since 1997, in particular in Belgium, France and
Italy. Denmark and the Netherlands remained the countries with
the lowest cephalosporin consumption in the community.4,5
Since 1997, the consumption of first-generation cephalosporins
in the community continued to decrease significantly, which could
be explained by the decreased or discontinued consumption of
cefadroxil, cefatrizine and cefradine, mainly in high cephalosporin
consuming countries such as France, Greece, Luxembourg, and
also in Portugal. The consumption of the older (first-generation)
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Figure 3. Estimated trend (solid line) and linear trend (dashed line) of consumption of cephalosporins (ATC J01DB, J01DC, J01DD and J01DE) in the
community based on quarterly data, 25 EU/EEA countries, 1997–2017. b0, predicted consumption in the first quarter of 1997; b1, predicted increase
(if positive)/decrease (if negative) in consumption per quarter; b2, predicted difference in slope after versus before the first change-point; b3, predicted
difference in slope after versus before the second change-point; b4, predicted difference in slope after versus before the third change-point; b0
S, pre-
dicted amplitude of the upward winter and downward summer peak in consumption; b1
S, predicted increase (if positive)/decrease (if negative) of the
amplitude of the upward winter and downward summer peak in consumption per quarter; d, shift in timing of the upward winter and downward
summer peak from one year to another. An asterisk indicates the result is statistically significant at significance level 0.05.
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(second- and third-generation) cephalosporins in most countries.
In 2017, second-generation cephalosporins were consumed twice
as much compared with 1997, which was due to the four-fold
increase of cefuroxime consumption. Observed increases in
the proportional consumption of second- and third-generation
cephalosporins are not only due to the decrease in the consump-
tion of first-generation cephalosporins, but also due to the increase
of the more extended-spectrum cephalosporins. Half of the
EU/EEA countries showed an increased consumption of third-
generation cephalosporins during 1997–2017. Fourth-generation
cephalosporins were consumed in 16 countries.
In a recently published study based on the ESAC-Net data
from the period 2001–2018, a decreasing trend was observed
for both in the community and hospital consumption of third-
generation cephalosporins in the EU/EEA. During the same
period, third-generation cephalosporin resistance percentages
in invasive Escherichia coli and Klebsiella pneumoniae isolates
seemed to be stabilizing, thus suggesting an effect of recent
public health efforts in promoting prudent antimicrobial use in
the EU/EEA.10
The highest proportions of parenterally administered cephalo-
sporins (mainly ceftriaxone) in the community were observed for
France, Greece, Italy and Latvia. In Italy, consumption of paren-
teral ceftriaxone increased until 2013 and decreased steadily
thereafter. Outpatient parenteral antimicrobial therapy (OPAT) is
common in Italy.11
Although cephalosporins are also used for the treatment of
urinary tract infections, and skin and soft tissue infections, the
observed seasonal variation in cephalosporin consumption
suggests that cephalosporins are mostly prescribed to treat
seasonal respiratory infections, which are often viral in nature,
and the prescriptions are therefore not following treatment
guidelines.12,13 However, confirmation of this hypothesis
would require information on the indication for cephalosporin
prescriptions.
The substantial variations between countries and over time
suggest that cephalosporins, in particular the more extended-
spectrum cephalosporins such as third-generation cephalosporins,
are to a large extent inappropriately used. In Bulgaria, a country
with high consumption of third-generation cephalosporins in the
community, the percentage of invasive isolates with acquired non-
susceptibility to third-generation cephalosporins reached 41.0% in
E. coli and 75.9% in K. pneumoniae in 2016.10 These resistance
percentages are considerably higher than in countries such as
Belgium, for which we observed a lower consumption of third-gen-
eration cephalosporins.14
With the exception of six cephalosporins that represented
<0.05% of cephalosporin consumption in the EU/EEA, all second-
and third-generation cephalosporins consumed in the EU/EEA are
listed as Watch group antibiotics in the 2019 WHO Access, Watch
or Reserve (AWaRe) classification list.15 The Watch group includes
antibiotics that have higher resistance potential than Access group
antibiotics and includes most of the highest priority agents among
the Critically Important Antimicrobials for Human Medicine.16 In
view of our observation that, in most EU/EEA countries, the
absolute and proportional consumption of second- and third-
generation cephalosporins significantly increased at the expense
of the consumption of first-generation cephalosporins, all second-
and third-generation cephalosporins should be prioritized as key
targets of stewardship programmes and monitoring in these
countries.
For a more-detailed discussion on the limitations of the
collected data, we refer to the article on antibacterials for systemic
use, included in this series.6 For a discussion on the limitations
of the statistical approach used in this study and potential explan-
ations for the common change-points detected through these
analyses, we refer readers to the tutorial included in this series.7
In conclusion, the longitudinal and compositional trends of
cephalosporin consumption in the community in EU/EEA countries
during 1997–2017 continued to follow the same patterns as al-
ready reported for 1997–2009, namely a significant increase in
consumption of the more extended-spectrum cephalosporins.
Further research is needed to better understand the observed
trends and seasonal variations. These results from ESAC-Net may
be used as a reference to gauge future interventions to optimize
cephalosporin consumption in the community in EU/EEA countries.
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